Gene Expression Analysis of Circulating Hormone Refractory Prostate Cancer
Annual rept. 1 Jan-31 Dec 2005
CALIFORNIA UNIV SAN FRANCISCO
Pagination or Media Count:
This annual report for the Physician Research Training Award focuses progress and challenges in the analysis of circulating hormone refractory prostate cancer micrometastases. Metastatic tissue for research is difficult to obtain in hormone refractory prostate cancer HRPC, as most metastatic sites are not conducive to biopsy. Circulating tumor cells CTCs have been found in high numbers in patients with metastatic HRPC and are easily accessible in the peripheral blood. Detecting genetic alterations that occur during the development of chemotherapy resistance will give insight into the mechanisms behind this resistance and determine potential therapeutic strategies to combat this resistance. Array CGH of CTCs will demonstrate the genomic changes that accompany the hormone refractory state, in addition to shedding light on genetic changes that occur with chemotherapy resistance. In addition to the genomic studies, CTC enumeration was used to determine the effect of CTC number on survival in patients receiving chemotherapy for HRPC. Work performed under this grant in 41 patients with metastatic HRPC has shown that patients with 1.8 CTCmL have a worse prognosis than patients with d1.8 CTCmL. The median survival of patients with metastatic HRPC with 1.8 CEC smL was 13 months. Median survival for patients with 1.8 CTC smL has not been reached. CTC s from chemotherapy refractory and chemotherapy na ve patients are being collected for genetic analysis.
- Medicine and Medical Research